Quest Diagnostics
DGX
657 hedge funds and large institutions have $11.2B invested in Quest Diagnostics in 2019 Q1 according to their latest regulatory filings, with 97 funds opening new positions, 235 increasing their positions, 201 reducing their positions, and 55 closing their positions.
76% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 55
18% more call options, than puts
Call options by funds: $68.3M | Put options by funds: $57.7M
17% more repeat investments, than reductions
Existing positions increased: 235 | Existing positions reduced: 201
12% more capital invested
Capital invested by funds: $10B → $11.2B (+$1.19B)
5% more funds holding
Funds holding: 625 → 657 (+32)
4.24% more ownership
Funds ownership: 88.67% → 92.92% (+4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$259M |
| 2 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
+$246M |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$101M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$49.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
-$122M |
| 2 |
APG Asset Management
Amsterdam,
Netherlands
|
-$102M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$64.8M |
| 4 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
-$48.9M |
| 5 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$36.2M |
DGX Hedge Fund Activity: Q1 2019 in Review
657 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2019, worth a combined $11.2B — up 12% from $10B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new DGX positions and 55 closed out — a net gain of 42 holders — while 235 added to existing stakes and 201 trimmed.
The largest buyer was Boston Partners, adding an estimated $259M. The largest seller was Levin Capital Strategies, cutting an estimated $122M.
- 657 institutional investors held Quest Diagnostics (DGX) as of Q1 2019, up from 625 in Q4 2018.
- Funds reported $11.2B of Quest Diagnostics stock for Q1 2019, up 12% quarter-over-quarter.
- 97 funds opened new Quest Diagnostics positions in Q1 2019 and 55 closed out, a net change of +42 holders.
- The largest Quest Diagnostics buyer in Q1 2019 was Boston Partners, an estimated $259M added.
- The largest Quest Diagnostics seller in Q1 2019 was Levin Capital Strategies, an estimated $122M sold.
Based on aggregated 13F filings for Q1 2019.